drugset / Trial / NCT00193258
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Phase 1/2
Completed
94 enrolled
SCRI Development Innovations, LLC
Genentech, Inc. · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial will evaluate the bevacizumab/erlotinib combination with the addition of imatinib (Gleevec). The combined inhibition greatly enhances the anti-tumor effects. Although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been demonstrated, the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity. A brief phase I portion will be included in this trial, to optimize doses of the 3 agents prior to proceeding with the phase II trial.
Timeline
- Start
- 2004-06
- Primary completion
- 2011-01
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Imatinib | Small molecule | 300 mg | Oral |
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Imatinib | Small molecule | 600 mg | Oral |